News

Delta variant increases hospitalisation but vaccine continues to protect

Hand holding a bottle marked 'Coronavirus' vaccine

  • Preliminary results of nationwide study    

The Delta variant of COVID-19 is associated with approximately double the risk of hospitalisation compared with the Alpha variant, according to a new nationwide study involving the University of Strathclyde.

Two vaccine doses still provide strong protection against the Delta variant – which was first identified in India – but it may be at a lower level compared with the Alpha variant, the early evidence suggests.

Based on data analysed from 5.4 million people in Scotland, the Delta variant is now the dominant form of COVID-19 cases in the country, overtaking the Alpha variant, which was first identified in Kent.

During the period studied – 1 April to 6 June 2021 – there were 19,543 community cases and 377 hospitalisations where a specific variant of COVID-19 was confirmed.

Of these totals, 7,723 cases and 134 hospitalisations were found to have the Delta variant. People with underlying conditions were more at risk of being hospitalised, researchers said.

The researchers say to increase confidence in these early findings, the research needs repeated in other countries and settings.

The team also say that because of the observational nature of the study, data about vaccine effectiveness should be interpreted with caution and it is not possible to make a direct comparison between both vaccines.

Professor Chris Robertson, Professor of Public Health Epidemiology in Strathclyde's Department of Mathematics and Statistics and Head of Statistics at Health Protection Scotland, was a partner in the study. He said: “It is important to recognise that these are preliminary results using rapidly accessible data. A fuller understanding will come when the results presented here are combined with similar analyses from other data sets in the UK”.

Dr Jim McMenamin, COVID-19 National Incident Director for Public Health Scotland said: “These results provide early encouragement that two doses of either Pfizer-BioNTech or Oxford-AstraZeneca vaccines significantly reduce the risk of infection against both the Alpha or new Delta variants. They also show the vaccines offer protection against the risk of hospitalisation with the new Delta variant. Though no vaccine can be 100% protective, they provide the best protection against COVID-19 and it remains important to get both doses when offered.”

Vaccines were found to reduce the risk of being admitted to hospital, but strong protective effects against the Delta variant were not seen until at least 28 days after the first vaccine dose.

In community cases at least two weeks after the second dose, the Pfizer-BioNTech vaccine was found to provide 79 per cent protection against infection from the Delta variant, compared with 92 per cent against the Alpha variant.

For the same scenario, the Oxford-AstraZeneca vaccine offered 60 per cent protection against infection with the Delta variant compared with 73 per cent for the Alpha variant. This lower vaccine effect may reflect that is takes longer to develop immunity with Oxford-AstraZeneca, experts say.

Delta variant cases were identified through initial PCR testing results, which reveal whether what is known as the S gene is present. Delta variant cases are positive for the S gene whilst Alpha variant cases tend to be S gene negative.

The research team from Strathclyde, the University of Edinburgh and Public Health Scotland, analysed a dataset as part of the EAVE II project, which uses anonymised linked patient data to track the pandemic and the vaccine roll out in real time.

The results are published as a research letter in The Lancet. Research letters are externally peer-reviewed, and their findings are usually preliminary or exploratory.

The study was funded by the Medical Research Council, UK Research and Innovation Industrial Strategy Challenge Fund and Health Data Research UK (HDR UK), and was supported by the Scottish Government.

Additional support was provided through the Scottish Government Director-General Health and Social Care, and the UKRI COVID-19 National Core Studies Data and Connectivity programme led by HDR UK.